Enloe Health has introduced a new heart procedure, the Left Atrial Appendage Closure (LAAC) surgery, or the "Watchman ...

The following is a summary of "In-hospital outcomes of cardiogenic shock patients: A propensity score-matched nationwide ...

WINT READ THE FULL WINT RESEARCH REPORT Multiple Programs Focus on Unmet Needs In Cardiogenic Shock & AHF Pennsylvania-based Windtree Therapeutics, Inc. (NASDAQ:WINT) is a biopharmaceutical company ...

Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative ...

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has filed a national phase patent application with the Indian ...

The 2025 guideline introduces notable updates including refined recommendations for dual antiplatelet therapy, cardiogenic ...

The recent study by Holger Thiele and colleagues1 offers an extensive meta-analysis on the use of mechanical circulatory support (MCS) in acute myocardial infarction-related cardiogenic shock (AMICS).

We thank our colleagues for their interest in our Article.1 We agree with Zaoqu Liu and colleagues that in addition to mortality assessment, quality of life and long-term functional outcomes are ...

The American College of Cardiology and American Heart Association issued updated practice guidelines for the management of ...

Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...

The American College of Cardiology and the American Heart Association today released an updated clinical practice guideline for managing individuals experiencing acute coronary syndrome (ACS). The ...